Tags

Type your tag names separated by a space and hit enter

Phenotype of subjects with type 2 diabetes mellitus may determine clinical response to chromium supplementation.
Metabolism 2007; 56(12):1652-5M

Abstract

Considerable controversy exists regarding the use of chromium (Cr) supplementation to modulate carbohydrate metabolism in subjects with diabetes. Recently, we reported that Cr supplementation, provided as 1000 microg/d as Cr picolinate, enhanced insulin sensitivity in subjects with type 2 diabetes mellitus. Our data agreed with some, but not all, studies that evaluated a similar dose and formulation in type 2 diabetes mellitus and suggested that subject selection and characteristics may be important considerations when assessing the clinical response. Thus, the goal of this study was to assess which metabolic or clinical characteristics, when obtained at baseline, best determine a clinical response to Cr when assessing changes in insulin sensitivity. Seventy-three subjects with type 2 diabetes mellitus were assessed in a double-blinded, randomized, placebo-controlled study. Subjects were assessed at baseline for glycemic control with glycated hemoglobin measures, oral glucose tolerance tests, and body weight and body fat measures (dual-energy x-ray absorptiometry). After baseline, insulin sensitivity in vivo was assessed with the use of hyperinsulinemic-euglycemic clamps. After the baseline clamp, subjects were randomized to receive Cr supplementation (1000 microg Cr/d provided as Cr picolinate) or placebo daily for 6 months. All study parameters were repeated after 6 months. The relationship of the baseline characteristics of the study subjects to the change in insulin sensitivity was determined. Sixty-three percent of the subjects with type 2 diabetes mellitus responded to the Cr treatment as compared with 30% with placebo. The only subject variable significantly associated with the clinical response to Cr was the baseline insulin sensitivity, as assessed with the hyperinsulinemic-euglycemic clamp (partial R(2) = .4038) (P = .0004). Subject phenotype appears to be very important when assessing the clinical response to Cr because baseline insulin sensitivity was found to account for nearly 40% of the variance in the clinical response to Cr.

Authors+Show Affiliations

Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA 70808, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

17998017

Citation

Wang, Zhong Q., et al. "Phenotype of Subjects With Type 2 Diabetes Mellitus May Determine Clinical Response to Chromium Supplementation." Metabolism: Clinical and Experimental, vol. 56, no. 12, 2007, pp. 1652-5.
Wang ZQ, Qin J, Martin J, et al. Phenotype of subjects with type 2 diabetes mellitus may determine clinical response to chromium supplementation. Metab Clin Exp. 2007;56(12):1652-5.
Wang, Z. Q., Qin, J., Martin, J., Zhang, X. H., Sereda, O., Anderson, R. A., ... Cefalu, W. T. (2007). Phenotype of subjects with type 2 diabetes mellitus may determine clinical response to chromium supplementation. Metabolism: Clinical and Experimental, 56(12), pp. 1652-5.
Wang ZQ, et al. Phenotype of Subjects With Type 2 Diabetes Mellitus May Determine Clinical Response to Chromium Supplementation. Metab Clin Exp. 2007;56(12):1652-5. PubMed PMID: 17998017.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Phenotype of subjects with type 2 diabetes mellitus may determine clinical response to chromium supplementation. AU - Wang,Zhong Q, AU - Qin,Jianhua, AU - Martin,Julie, AU - Zhang,Xian H, AU - Sereda,Olga, AU - Anderson,Richard A, AU - Pinsonat,Patricia, AU - Cefalu,William T, PY - 2007/05/22/received PY - 2007/07/10/accepted PY - 2007/11/14/pubmed PY - 2008/1/9/medline PY - 2007/11/14/entrez SP - 1652 EP - 5 JF - Metabolism: clinical and experimental JO - Metab. Clin. Exp. VL - 56 IS - 12 N2 - Considerable controversy exists regarding the use of chromium (Cr) supplementation to modulate carbohydrate metabolism in subjects with diabetes. Recently, we reported that Cr supplementation, provided as 1000 microg/d as Cr picolinate, enhanced insulin sensitivity in subjects with type 2 diabetes mellitus. Our data agreed with some, but not all, studies that evaluated a similar dose and formulation in type 2 diabetes mellitus and suggested that subject selection and characteristics may be important considerations when assessing the clinical response. Thus, the goal of this study was to assess which metabolic or clinical characteristics, when obtained at baseline, best determine a clinical response to Cr when assessing changes in insulin sensitivity. Seventy-three subjects with type 2 diabetes mellitus were assessed in a double-blinded, randomized, placebo-controlled study. Subjects were assessed at baseline for glycemic control with glycated hemoglobin measures, oral glucose tolerance tests, and body weight and body fat measures (dual-energy x-ray absorptiometry). After baseline, insulin sensitivity in vivo was assessed with the use of hyperinsulinemic-euglycemic clamps. After the baseline clamp, subjects were randomized to receive Cr supplementation (1000 microg Cr/d provided as Cr picolinate) or placebo daily for 6 months. All study parameters were repeated after 6 months. The relationship of the baseline characteristics of the study subjects to the change in insulin sensitivity was determined. Sixty-three percent of the subjects with type 2 diabetes mellitus responded to the Cr treatment as compared with 30% with placebo. The only subject variable significantly associated with the clinical response to Cr was the baseline insulin sensitivity, as assessed with the hyperinsulinemic-euglycemic clamp (partial R(2) = .4038) (P = .0004). Subject phenotype appears to be very important when assessing the clinical response to Cr because baseline insulin sensitivity was found to account for nearly 40% of the variance in the clinical response to Cr. SN - 0026-0495 UR - https://www.unboundmedicine.com/medline/citation/17998017/Phenotype_of_subjects_with_type_2_diabetes_mellitus_may_determine_clinical_response_to_chromium_supplementation_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0026-0495(07)00269-7 DB - PRIME DP - Unbound Medicine ER -